Overcoming Clinical Challenges in BRIC Markets - China - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Overcoming Clinical Challenges in BRIC Markets - China Thomson Reuters Cortellis Competitive Intelligence

Source: Applied Clinical Trials

Read the companion parts of this report on Brazil , Russia, and India.

4E: Late-stage trials are the most prevalent in India, with top therapeutic areas mimicking the global trend: diabetes, pulmonary diseases, and rheumatoid arthritis.

5A: China is the only BRIC country seeing an increase in the amount of clinical trials they are initiating every year. And clearly, large pharma lags behind Chinese-based trial initiations in that country. Recent developments in partnerships include AstraZeneca’s with Beijing’s premier clinical research laboratory, Pharmaron. Extensive networks of on-ground expertise with CROs is growing with entities like Novartis, Quintiles, Parexel, Covance’s central laboratory, and Catalant’s recently opened clinical trial supply facility in shanghai.

5E: Phase I trials must be performed in China with Chinese patients for all new drugs not already registered in another country. Due to the high incidence of local sponsors, however, early-stage trials are relatively elevated compared to other BRIC countries. Phase III trials are being initiated in oncology and pulmonology in numbers close to those of early-stage trials, which focus mainly on oncology.

SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here.

 

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here